A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. - Wikidata - wikimedia - TriplyDB

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

http://www.wikidata.org/entity/Q43052325

about

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions Current management and prognostic features for gastrointestinal stromal tumor (GIST)Gastrointestinal stromal tumors in kidney transplant recipients: Report of two cases and literature review.Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.A gist of gastrointestinal stromal tumors: A review.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Recent advances and novel agents for gastrointestinal stromal tumor (GIST)New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS)Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.Update on imatinib for gastrointestinal stromal tumors: duration of treatment.Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.Reintroduction of imatinib in GIST Targeted therapy for sarcomas.Gastrointestinal stromal tumors: morphological, immunohistochemical and molecular changes associated with kinase inhibitor therapy.Current and emerging pharmacological treatments for gastrointestinal stromal tumour.Targeted therapy in GIST: in silico modeling for prediction of resistance.New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.Management of gastrointestinal stromal tumors.Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.Regorafenib for treatment of advanced gastrointestinal stromal tumors.Controversies in the management of gastrointestinal stromal tumors.GIST treatment options after tyrosine kinase inhibitors.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.Emerging drugs for the treatment of gastrointestinal stromal tumour.

P2860

Q26799387-8B152740-8522-4E46-9704-7FB59546B0B0 Q28391684-DE5D73E5-6AA8-459C-A3F9-73B2B230B983 Q30248777-DC74A447-5058-40E9-85F8-F201EF3ABD10 Q33810494-05B9C5C6-DCBB-4846-9A7C-88997791439E Q34499075-32B111E9-C8C1-4137-AE9A-B8C249F642BE Q34654203-23D1D635-DB0F-40AF-B09E-A996617047DA Q34957090-5C0EBC77-9148-4BC1-A63F-09AD8915DB62 Q36118178-1D280FBE-C432-44CB-BE74-8515457A8BBD Q36144084-7FA34AA7-7D9F-4EE6-8176-ACA9759D700C Q36144210-EB674BF6-9288-454D-A473-359428B177AB Q36180074-B0F29CD6-06B5-47B6-B201-2E34A81D3EAF Q36561734-2FF838BB-ACA6-4DA0-AFA2-7C92A7621698 Q36910431-DB4E9306-1E4A-4E9D-BA89-9A0C9BEFB040 Q36998239-F5EC4D76-4D74-4E38-AF38-F4666253D092 Q37075052-452A1499-407C-4CCB-AD58-BB012E335796 Q37131708-C87D45F6-BB98-4B3E-80E3-E2BF30C6744F Q37220191-AAAED371-79B8-4B27-BB5B-E2D60B19133F Q37301364-3A3C0BD1-705E-482A-A7A0-C00927D81C19 Q37655450-CA4FB487-15F4-4C9D-BF05-6AA85695CFA4 Q37833541-BC3CB68E-4B6D-4703-8B44-7FF181749D6B Q37841551-706089EF-E3AB-4D56-A9DC-D293204BB085 Q37848666-0D2B7EC4-690B-4444-8E7C-690AAF4A75B0 Q37850810-501DEDBE-A977-4D49-A59B-18F0B4FE6575 Q37954207-8FBD254D-FB8C-4FCF-B3B2-DAC52CD756CE Q38081983-60850EB4-EF79-45B0-BF7C-0AD2F32A0DBA Q38100719-78BD7CBF-25B4-49A6-A7D4-0071CA6B9969 Q38112821-AE961748-13D2-4FAC-A84A-72E696368B3A Q38120079-30AD9B23-A39F-444C-B191-EB08F48D90FE Q38131047-2EA9A9B0-1A4A-4E2B-8053-922A86DC741B Q38176966-56BEB35E-8E17-4800-B1F6-1F40B569F922 Q38199797-69739225-3854-4C63-846C-186D04F9D4A1 Q38222205-26BECA48-ABB5-4290-8C8D-560B8EDCD800 Q38268165-1D237AD4-3C41-4999-ADF7-8ED559F74EB7 Q38527941-03A59252-FA45-40F1-B38F-12E1323F8ED2 Q38714062-3F12B432-2C67-455F-9FD3-3C89DA978AA0 Q38925022-30EF4E23-5E6C-4836-860B-AF52F1981A55 Q39288497-CEFFCEF6-A04F-4102-9C12-FBCA05332CF6 Q41694334-FFEB6E5D-4999-49FE-BB77-D6EB2F2EEBE7 Q45743838-6F18E479-F7C5-4FDC-9ECD-C52040B69112 Q47355982-E32831EC-DFF8-40FD-A983-D090904647FF

P2860

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

http://www.wikidata.org/entity/Q43052325

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

A phase I-II study of everolim ...... strointestinal stromal tumors.

@en

A phase I-II study of everolimus

@nl

type

label

A phase I-II study of everolim ...... strointestinal stromal tumors.

@en

A phase I-II study of everolimus

@nl

prefLabel

A phase I-II study of everolim ...... strointestinal stromal tumors.

@en

A phase I-II study of everolimus

@nl

P1433

Q43052325-66366BAD-3677-40DD-A761-CB941AC514D3

P1476

Q43052325-8BEC5819-7861-4D00-BE03-3184A2827E9C

P2093

Q43052325-098C4B66-93A8-469F-AF04-0CB1D83FED7E

Q43052325-24851641-6985-429D-9359-7DFED5D161D6

Q43052325-648A3043-6988-47D1-8B01-C81D410559D7

Q43052325-7B7B3E26-B09D-4B7B-BEA2-E2B2B01F42DB

Q43052325-A24DDB0B-0A54-45AE-B9D7-BA09E841286E

Q43052325-A7E81F14-ABCC-4419-8910-BDF9E6ADC4CC

Q43052325-B785B1DB-F8A9-492C-B89B-FB64E69F8DBE

Q43052325-BDC5F0BD-0E46-4225-BCB0-4C327A1B2152

P2860

Q43052325-0599410B-8158-4444-A8DA-3AE252815DAB

Q43052325-0709AC9A-C266-42EF-9941-33E1D0578B0E

Q43052325-12D18B51-6250-4BAF-A2CD-2B9016516406

Q43052325-1B52AEE4-358C-4A2B-A9EE-1ED763D29EC5

Q43052325-1C6DB16C-76F3-4C84-8668-DE3440967877

Q43052325-223B899C-10D5-446C-B773-37EEE61035C8

Q43052325-39F2820D-B062-4F44-8F4A-BC27298787BA

Q43052325-3A55BE41-FC1C-4A32-925F-B7CE5E492892

Q43052325-3CEF56E5-E5B9-4AFF-A4B7-82809EF0C7E1

Q43052325-4FD736E2-B202-4DD6-AFBC-40C96E2DDB28

P304

Q43052325-CFC302B1-51BD-4E08-86AC-467ADFD6CE8F

P31

Q43052325-2A309D33-E3D7-4DAF-8812-DACDDB7157A8

P356

Q43052325-E869E0F2-B215-421F-84C1-A7433BF1CCC0

P433

Q43052325-C288447F-9532-4A21-8991-9D2C1719DBCD

P478

Q43052325-84DC0DAB-0F00-4353-A2E0-BDD66A2B37D4

P50

Q43052325-E626504B-6429-484A-9C28-CC8F4CA57522

P577

Q43052325-D938C289-9E1F-47A1-8DE0-9C0DD5D231AF

P5875

Q43052325-3165B2AF-A13F-4E29-80B2-8DF5517C2457

P698

Q43052325-DADAEF2E-5358-47CE-88EC-0CF3E288AC08

P356

P1433

Annals of Oncology

P1476

A phase I-II study of everolim ...... strointestinal stromal tumors.

@en

P2093

A Jappe

http://www.w3.org/2001/XMLSchema#string

G D Demetri

http://www.w3.org/2001/XMLSchema#string

H Dumez

http://www.w3.org/2001/XMLSchema#string

I Ray-Coquard

http://www.w3.org/2001/XMLSchema#string

J A Morgan

http://www.w3.org/2001/XMLSchema#string

N Hollaender

http://www.w3.org/2001/XMLSchema#string

P Reichardt

http://www.w3.org/2001/XMLSchema#string

P Schöffski

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

TOR signaling in growth and metabolism

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Current development of mTOR inhibitors as anticancer agents

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

PDGFRA activating mutations in gastrointestinal stromal tumors.

P304

1990-1998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ076

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44635493

http://www.w3.org/2001/XMLSchema#string

P698

20507881

http://www.w3.org/2001/XMLSchema#string